Lung Cancer: Page 5

Qiagen inks deal with Mirati on cancer companion diagnostic

By LabPulse.com staff writers

The agreement initially focuses on a companion diagnostic test for nonsmall cell lung cancer and allows for further development of tests for other Mirati oncology programs. The planned companion diagnostic would expand upon Qiagen's therascreen KRAS testing portfolio. Qiagen and Mirati have previously partnered for the development of a companion diagnostic.

May 25, 2021

Nucleix secures $55M in funding for lung cancer test

Nucleix will use the financing to continue to advance its methylation technology and the blood-based assay. The test analyzes subtle, disease-specific changes in DNA methylation markers in patients, specifically current and former smokers.

April 6, 2021

Delfi begins lung cancer study

By LabPulse.com staff writers

The prospective study will compare the performance of Delfi's test in diagnosing lung cancer in a group of 1,700 patients already known to have cancer with a demographically matched cohort of presumably healthy patients, according to the company.

March 31, 2021

Universal Diagnostics touts blood-based lung cancer test

By LabPulse.com staff writers

Presented at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference, the test uses methylation status measurement of the tumor-derived portion from cell-free DNA (cfDNA) in plasma for patient classification. Researchers examined plasma samples of 37 lung cancer patients and 71 asymptomatic age, gender, and smoking-history matching controls.

January 28, 2021

Delfi raises $100M to develop liquid biopsy for multiple cancers

By LabPulse.com staff writers

Delfi said its technology leverages recent discoveries in the genome-wide fragmentation profiles of cell-free DNA to detect evidence of tumors from blood samples, and also has the capability to pinpoint the location of tumors in the body. Delfi plans to develop a range of products for detecting specific cancers, such as lung cancer, in at-risk individuals, as well as to identify multiple types of cancers in any individual.

January 12, 2021

Falling lung cancer rates drive cancer decline in U.S. over past 2 decades

By Emily Hayes

The report found that in 2020, the cancer death rate was down by 31% compared with 1991, including a 2.4% decrease between 2017 and 2018, the ACS reported. The findings are in line with prior reports showing cancer death rates overall dropping in recent years.

January 11, 2021

FDA clears Foundation Medicine's liquid biopsy test

By LabPulse.com staff writers

FoundationOne Liquid CDx can be used as a companion diagnostic for four cancer therapies, including rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor for metastatic prostate cancer patients with BRCA1/2 mutations, and three epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer patients.

August 26, 2020

Cancer research groups partner for liquid biopsy trial

By LabPulse.com staff writers

In a phase II, multicenter trial, researchers from the Canadian Cancer Trial Group will first investigate whether changes in circulating cell-free tumor DNA (ctDNA) can better predict immunotherapy response than radiographic assessments. They will then examine whether ctDNA patterns can guide treatment decisions for patients with non-small cell lung cancer.

July 29, 2020

Stilla unveils 6-color digital PCR instrument

By LabPulse.com staff writers

Expanding the multiplexing capabilities of Stilla's Naica digital PCR platform, Prism has been validated for use with a six-color lung cancer panel for EGFR mutation quantification, for liquid-biopsy monitoring in breast and rectal cancer, and for detecting and quantifying genetically modified organisms in the food supply, according to the firm.

June 8, 2020

Genomic profiling uncovers treatment resistance in lung cancer patients

By Emily Hayes

Many different kinds of new treatments are now available for NSCLC, including immunotherapies and targeted drugs for molecular subtypes, such as MET inhibitors for the 3% of patients with skipping of exon 14 on the MET gene -- METex14-altered disease. The study presented at ASCO, however, uncovered co-occurring alterations that may render patients with METex14-altered NSCLC resistant to treatment with MET inhibitors. Results also suggest that the METex14-altered type can be further broken down into distinct subclasses, allowing for a more precise diagnosis and targeted treatment regimens.

May 31, 2020

Survey: Molecular testing greatly underused in lung cancer patients

By Emily Hayes

The survey was conducted anonymously and online by the International Association for the Study of Lung Cancer (IASLC). It included medical oncologists ordering tests, pathologists making the interpretations, and nonclinical scientists, with questions adapted based on specialty and role.

May 25, 2020

FDA approves Agilent assay for lung cancer

By LabPulse.com staff writers

The test, called PD-L1 IHC 28-8 pharmDx, will help physicians identify patients with metastatic NSCLC who qualify for treatment with a dual immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy), both of which are manufactured by Bristol Myers Squibb.

May 17, 2020

Previous Page

Page 5 of 7

Next Page